{
    "clinical_study": {
        "@rank": "53813", 
        "arm_group": {
            "arm_group_label": "Amiloride", 
            "arm_group_type": "Experimental", 
            "description": "This is a non-randomized and non-controlled study with only one treatment arm with amiloride."
        }, 
        "brief_summary": {
            "textblock": "To evaluate the antihypertensive effect of amiloride added to triple antihypertensive\n      therapy in patients with resistant hypertension (RH) and type 2 diabetes mellitus (T2DM)"
        }, 
        "brief_title": "Amiloride for Resistant Hypertension", 
        "completion_date": {
            "#text": "August 2012", 
            "@type": "Actual"
        }, 
        "condition": [
            "Hypertension", 
            "Type 2 Diabetes Mellitus", 
            "Microalbuminuria"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Hypertension", 
                "Albuminuria"
            ]
        }, 
        "detailed_description": {
            "textblock": "The primary objective of this study was to evaluate the antihypertensive effect of amiloride\n      added to triple antihypertensive treatment in patients with resistant hypertension and type\n      2 diabetes mellitus in an open-labelled, non- controlled and non-randomized interventional\n      study.\n\n      The secondary objectives were to evaluate the additional effects of amiloride on:\n\n        -  Urinary albumin excretion\n\n        -  Blood pressure control, how many patients reached blood pressure control when amiloride\n           was added to previous triple antihypertensive treatment.\n\n        -  Plasminogen and plasmin excretion (ENaC activity) in the micro-and macroalbuminuric\n           patients in the cohort.\n\n        -  Urokinase plasminogen activator (uPA) activity"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  diagnosed with resistant hypertension (average daytime BP >130and/or >80 mmHg by\n             ambulatory monitoring in spite of treatment with 3 antihypertensive drugs including a\n             diuretic and an  angiotensin coverting enzyme inhibitor (AECi) or angiotensin\n             recpetor blocker (ARBs) and a third optional, all in optimal dosages.\n\n          -  type 2 diabetes\n\n          -  prior participant in a randomized controlled trial with spironolactone, but after a\n             wash-out periods of minimum two weeks (NCT01062763)\n\n        Exclusion Criteria:\n\n          -  Office blood pressure (BP) >180/110 mmHg\n\n          -  daytime average BP by ambulatory monitoring > 170/85 mmHg\n\n          -  heart failure (NYHA III-IV) Cardiac arrythmia HbA1C > 10% severe dyslipidemia known\n             or with signs of secondary hypertension estimated glomerular filtration rate (eGFR)\n             <50ml/min per 1.73 m2 prior intolerance to spironolactone or amiloride fertility\n             without oral contraception pregnancy lactation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 23, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02122731", 
            "org_study_id": "EudraCT 2009-017033"
        }, 
        "intervention": {
            "arm_group_label": "Amiloride", 
            "description": "5 mg(daily of amiloride was added to patients triple antihypertensive therapy and increased to 10 mg/daily if office blood pressure at 4 weeks was above 130/80 mmHg.", 
            "intervention_name": "Amiloride", 
            "intervention_type": "Drug", 
            "other_name": "Amiloride"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Amiloride", 
                "Antihypertensive Agents"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "antihypertensive therapy", 
            "amiloride", 
            "add-on", 
            "resistant hypertension", 
            "blood pressure control", 
            "type 2 diabetes mellitus,", 
            "microalbuminuria."
        ], 
        "lastchanged_date": "April 23, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Esbjerg", 
                        "country": "Denmark"
                    }, 
                    "name": "Sydvestjysk Hospital, Esbjerg"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fredericia", 
                        "country": "Denmark"
                    }, 
                    "name": "Sygehus Lillebaelt."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gentofte", 
                        "country": "Denmark"
                    }, 
                    "name": "Steno Diabetes Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Odense", 
                        "country": "Denmark"
                    }, 
                    "name": "Odense University Hospital, Department of Endocrinology"
                }
            }
        ], 
        "location_countries": {
            "country": "Denmark"
        }, 
        "number_of_arms": "1", 
        "official_title": "Southern Danish Hypertension and Diabetes Study (SDHDS) With Amiloride", 
        "overall_official": {
            "affiliation": "Department of endocrinology, Odense University Hospital, Odense, Denmark", 
            "last_name": "Ib A Jacobsen, DMSc", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Denmark: Danish Medicines Agency", 
                "Denmark: National Board of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "July 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "ambulatory blood pressure monitoring was performed at baseline and after 8 weeks intervention with amiloride", 
            "measure": "average daytime systolic and diastolic blood pressure", 
            "safety_issue": "Yes", 
            "time_frame": "8 weeks"
        }, 
        "reference": {
            "PMID": "24107738", 
            "citation": "Oxlund CS, Henriksen JE, Tarnow L, Schousboe K, Gram J, Jacobsen IA. Low dose spironolactone reduces blood pressure in patients with resistant hypertension and type 2 diabetes mellitus: a double blind randomized clinical trial. J Hypertens. 2013 Oct;31(10):2094-102. doi: 10.1097/HJH.0b013e3283638b1a."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02122731"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Odense University Hospital", 
            "investigator_full_name": "Ib Abildgaard Jacobsen", 
            "investigator_title": "Consultant Physician", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Urine albumin was measured at baseline and after 8 weeks of amiloride treatment.", 
                "measure": "Urinary albumin excretion", 
                "safety_issue": "Yes", 
                "time_frame": "after 8 weeks"
            }, 
            {
                "description": "plasma potassium tend to increase during amiloride treatment", 
                "measure": "plasma potassium", 
                "safety_issue": "Yes", 
                "time_frame": "after 4 and 8 weeks"
            }, 
            {
                "description": "uPA exist in urine where it cleaves plasminogen to plasmin. uPA is possible secreted fra the tubulus cells", 
                "measure": "urinary urokinase plasminogen activator (uPA) activity", 
                "safety_issue": "No", 
                "time_frame": "At baseline and after 8 weeks of amiloride treatment"
            }, 
            {
                "description": "U-plasminogen is filtered to urine in patients with microalbuminuria. In urine plasminogen is activated to plasmin by urokinase plasminogen activator.Plasmin activates the epithelial sodium channel.", 
                "measure": "urine plasminogen and plasmin", 
                "safety_issue": "No", 
                "time_frame": "at baseline and after 8 weeks of amiloride treatment"
            }
        ], 
        "source": "Odense University Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ib Abildgaard Jacobsen", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2010", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}